Abstract is: Piperacillin/tazobactam, sold under the brand name Zosyn among others, is a combination medication containing the antibiotic piperacillin and the β-lactamase inhibitor tazobactam. The combination has activity against many Gram-positive and Gram-negative bacteria including Pseudomonas aeruginosa. It is used to treat pelvic inflammatory disease, intra-abdominal infection, pneumonia, cellulitis, and sepsis. It is given by injection into a vein. Common adverse effects include headache, trouble sleeping, rash, nausea, constipation, and diarrhea. Serious adverse effects include Clostridium difficile infection and allergic reactions including anaphylaxis. Those who are allergic to other β-lactam are more likely to be allergic to piperacillin/tazobactam. Use in pregnancy or breastfeeding appears to generally be safe. It usually results in bacterial death through blocking their ability to make a cell wall. Piperacillin/tazobactam was approved for medical use in the United States in 1993. It is on the World Health Organization's List of Essential Medicines. It is available as a generic medication.
type of mixture of chemical entities | Q119892838 |
combination drug | Q1779868 |
P2067 | mass | 817.21596 | |
P3489 | pregnancy category | US pregnancy category B | Q28123616 |
P2868 | subject has role | essential medicine | Q35456 |
P12081 | WHO Aware Classification | watch | Q122925721 |
Description: A bottle of piperacillin tazobactam
Artist: James Heilman, MD
Work is copyrighted.
License: CC BY-SA 4.0
Attribution is required.
Q59333959 | 1067. Comparative Effectiveness of Nafcillin or Oxacillin, Cefazolin, and Piperacillin/Tazobactam in Methicillin-Sensitive Staphylococcus aureus Bacteremia |
Q94121951 | 1149. Reducing Piperacillin/Tazobactam Use in Children with Acute Perforated Appendicitis |
Q59327902 | 1414. Inoculum Effect of Piperacillin/Tazobactam Concentration on Emergence of Resistance in Klebsiella aerogenes |
Q59333772 | 1416. Piperacillin/Tazobactam Therapeutic Drug Monitoring: True Interpatient Variability or Compound Instability? |
Q94128859 | 2166. Performance Study on the New ETEST® Piperacillin/Tazobactam (P/T) MIC Strip |
Q94142228 | 2244. Clinical Outcomes with Extended Infusion (EI) vs. Intermittent Infusion (II) of Cefepime (FEP), Piperacillin/Tazobactam (TZP), and Meropenem (MEM) in Patients with Gram-Negative (GN) Bacteremia |
Q94141522 | 2292. Incidence of Acute Kidney Injury Associated with Duration of Vancomycin and Piperacillin/tazobactam Combination Therapy |
Q94142897 | 2385. Evaluating the Antibiotic Risk for Clostridioides difficile Infection (CDI): Comparing Piperacillin/Tazobactam to Cefepime and Ceftazidime |
Q59334245 | 2407. Emerging Piperacillin/Tazobactam Resistance in Escherichia coli and Klebsiella sp |
Q59328409 | 2432. Appropriateness of Empiric Extended-Infusion Piperacillin/Tazobactam in the Intensive Care Unit |
Q59328022 | 2436. Use of Piperacillin/Tazobactam vs. Cefepime or Carbapenem for Infections Due to Serratia, Citrobacter, or Enterobacter |
Q59327348 | 2442. Outcomes in ESBL Bacteremia Empirically Treated With Piperacillin/Tazobactam or Carbapenems |
Q94141517 | 2687. Extended Infusions of Piperacillin/Tazobactam vs. Cefepime for Empiric Treatment of Neutropenic Fever |
Q94133410 | 400. Comparison of Tolerance and Microbiological Efficacy of Cefepime and Piperacillin/Tazobactam in Combination with Vancomycin as Empirical Antimicrobial Therapy of Prosthetic Joint Infection: A Propensity-Matched Cohort Study |
Q100514715 | A Much-Anticipated Leap Forward in β-Lactam Drug Allergy: Phenotyping Reactions to Piperacillin/Tazobactam |
Q98390736 | A Randomized, Double-blind, Multicenter Trial Comparing Efficacy and Safety of Imipenem/Cilastatin/Relebactam Versus Piperacillin/Tazobactam in Adults With Hospital-acquired or Ventilator-associated Bacterial Pneumonia (RESTORE-IMI 2 Study) |
Q90284827 | A Randomized, Open-Labeled, Prospective Controlled Study to Assess the Efficacy of Frontline Empirical Intravenous Piperacillin/Tazobactam Monotherapy in Comparison with Ceftazidime Plus Amikacin for Febrile Neutropenia in Pediatric Oncology Patient |
Q45274805 | A comparison of intravitreal piperacillin/tazobactam with ceftazidime in experimental Pseudomonas aeruginosa endophthalmitis |
Q44270987 | A multicenter clinical trial of piperacillin/tazobactam in burn infection |
Q71654587 | A multicentre in vitro evaluation of piperacillin/tazobactam in Germany |
Q33438606 | A propensity score-matched analysis of the impact of minimum inhibitory concentration on mortality in patients with Pseudomonas aeruginosa bacteraemia treated with piperacillin/tazobactam |
Q53668374 | A prospective randomized trial comparing piperacillin/tazobactam with meropenem as empirical antibiotic treatment of febrile neutropenic children and adolescents with hematologic and malignant disorders. |
Q73465204 | A randomized controlled clinical trial on piperacillin/tazobactam versus ticarcillin/clavulanic acid for the treatment of bacterial infections |
Q72956657 | A randomized multicenter trial of piperacillin/tazobactam versus imipenem/cilastatin in the treatment of severe intra-abdominal infections. Swedish Study Group |
Q35328383 | A randomized trial of the efficacy and safety of sequential intravenous/oral moxifloxacin monotherapy versus intravenous piperacillin/tazobactam followed by oral amoxicillin/clavulanate for complicated skin and skin structure infections |
Q72826433 | A reminder: piperacillin/tazobactam is not for Pseudomonas |
Q57728123 | A validated LC–MS/MS method for the quantification of piperacillin/tazobactam on dried blood spot |
Q39929915 | Accounting for the development of antibacterial resistance in the cost effectiveness of ertapenem versus piperacillin/tazobactam in the treatment of diabetic foot infections in the UK. |
Q54034077 | Activity of piperacillin/tazobactam in combination with amikacin, ciprofloxacin, and trovafloxacin against Pseudomonas aeruginosa by time-kill. |
Q54342220 | Activity of ticarcillin/clavulanate and piperacillin/tazobactam (YTR 830; CL-298,741) against clinical isolates and against mutants derepressed for class I beta-lactamase. |
Q50124154 | Acute Kidney Injury in Hematopoietic Cell Transplantation Patients Receiving Vancomycin and Piperacillin/Tazobactam Versus Vancomycin and Cefepime |
Q37097893 | Acute Kidney Injury in Patients on Concomitant Vancomycin and Piperacillin/Tazobactam: Are Extended Infusions to Blame? |
Q90541009 | Acute eosinophilic pneumonia due to piperacillin/tazobactam |
Q88646537 | Acute kidney injury associated with concomitant vancomycin and piperacillin/tazobactam administration: a systematic review and meta-analysis |
Q40195923 | Acute kidney injury risk associated with piperacillin/tazobactam compared with cefepime during vancomycin therapy in hospitalised patients: a cohort study stratified by baseline kidney function |
Q87029822 | Acute localized exanthematous pustulosis on inguinal area secondary to piperacillin/tazobactam |
Q44732727 | Alveolar concentrations of piperacillin/tazobactam administered in continuous infusion to patients with ventilator-associated pneumonia |
Q91135287 | Aminoglycoside versus carbapenem or piperacillin/tazobactam treatment for bloodstream infections of urinary source caused by Gram-negative ESBL-producing Enterobacteriaceae |
Q73328451 | An evaluation of the bactericidal activity of ampicillin/sulbactam, piperacillin/tazobactam, imipenem or nafcillin alone and in combination with vancomycin against methicillin-resistant Staphylococcus aureus (MRSA) in time-kill curves with infected |
Q71354387 | An evaluation of the in vitro activity of piperacillin/tazobactam |
Q43758478 | An observational study on the epidemiology of respiratory tract bacterial pathogens and their susceptibility to four injectable beta-lactam antibiotics: piperacillin, piperacillin/tazobactam, ceftazidime and ceftriaxone |
Q53989640 | An open, multicenter clinical trial of piperacillin/tazobactam in the treatment of pediatric patients with intra-abdominal infections. |
Q44294929 | An open-label, randomized study comparing efficacy and safety of intravenous piperacillin/tazobactam and ampicillin/sulbactam for infected diabetic foot ulcers |
Q79986962 | Antibacterial activity of tazocin (piperacillin/tazobactam) against 1296 clinical isolates from a tertiary care center |
Q79385930 | Antibiotic prophylaxis in hernia repair and breast surgery: a prospective randomized study comparing piperacillin/tazobactam versus placebo |
Q43263131 | Antipseudomonal activity of piperacillin/tazobactam: more than a decade of experience from the SENTRY Antimicrobial Surveillance Program (1997-2007). |
Q60198307 | Assessing antimicrobial stewardship initiatives: Clinical evaluation of cefepime or piperacillin/tazobactam in patients with bloodstream infections secondary to AmpC-producing organisms |
Q47230552 | Assessing the Effect of Piperacillin/Tazobactam on Hematological Parameters in Patients Admitted with Moderate or Severe Foot Infections |
Q40424803 | Assessing the risk of false positive serum galactomannan among patients receiving piperacillin/tazobactam for febrile neutropenia |
Q99726946 | Assessment of the stability of citrate-buffered piperacillin/tazobactam for continuous infusion when stored in two commercially available elastomeric devices for outpatient parenteral antimicrobial chemotherapy: a study compliant with the NHS Yellow |
Q101237853 | Association between minimum inhibitory concentration, beta-lactamase genes and mortality for patients treated with piperacillin/tazobactam or meropenem from the MERINO study |
Q41991618 | Association of Acute Kidney Injury With Concomitant Vancomycin and Piperacillin/Tazobactam Treatment Among Hospitalized Children |
Q35100125 | Bacterial susceptibilities to piperacillin/tazobactam in a tertiary care hospital: 5-year review |
Q45911239 | Balancing the Efficacy and Safety of Implementing a Piperacillin/tazobactam (PTZ) Antibiotic Time-out. |
Q54232073 | Behaviour of beta-lactamase-positive and -negative Staphylococcus aureus isolates in susceptibility tests with piperacillin/tazobactam and other beta-lactam/beta-lactamase inhibitor combinations. |
Q60922047 | Bloodstream Infection due to Piperacillin/Tazobactam Non-Susceptible, Cephalosporin-Susceptible : A Missed Opportunity for De-Escalation of Therapy |
Q70493359 | Breakpoint determination: piperacillin/tazobactam |
Q42201138 | Carbapenems and piperacillin/tazobactam for the treatment of bacteremia caused by extended-spectrum β-lactamase-producing Proteus mirabilis |
Q40312112 | Cefepime versus piperacillin/tazobactam with or without amikacin in the treatment of febrile hematological and oncological neutropenic patients in an internal medicine ward |
Q44176569 | Cefepime, piperacillin/tazobactam, gentamicin, ciprofloxacin, and levofloxacin alone and in combination against Pseudomonas aeruginosa |
Q47164903 | Cefoxitin vs. Piperacillin/Tazobactam for Acute Appendicitis in Pediatric Patients |
Q64947381 | Cefuroxime compared to piperacillin/tazobactam as empirical treatment of Escherichia coli bacteremia in a low Extended-spectrum beta-lactamase (ESBL) prevalence cohort. |
Q34520874 | Clinafloxacin versus piperacillin/tazobactam in the treatment of severe skin and soft-tissue infections in adults at a Veterans Affairs medical center |
Q100644011 | Clinical Benefits of Piperacillin/Tazobactam versus a Combination of Ceftriaxone and Clindamycin in the Treatment of Early, Non-Ventilator, Hospital-Acquired Pneumonia in a Community-Based Hospital |
Q40078698 | Clinical Outcomes of Extended Versus Intermittent Infusion of Piperacillin/Tazobactam in Critically Ill Patients: A Prospective Clinical Trial. |
Q85924935 | Clinical and microbiological results following nonsurgical periodontal therapy with or without local administration of piperacillin/tazobactam |
Q46159338 | Clinical cure of ventilator-associated pneumonia treated with piperacillin/tazobactam administered by continuous or intermittent infusion |
Q40388018 | Clinical effects and safety of piperacillin/tazobactam in treating neutropenic febrile patients with malignant hematopathy |
Q39382608 | Clinical efficacy of piperacillin/tazobactam in the treatment of complicated skin and soft tissue infections |
Q91991786 | Clinical outcomes following treatment of Enterobacter species pneumonia with piperacillin/tazobactam compared to cefepime or ertapenem |
Q37642084 | Clinical outcomes of extended versus intermittent administration of piperacillin/tazobactam for the treatment of hospital-acquired pneumonia: a randomized controlled trial |
Q34892334 | Clinical outcomes with alternative dosing strategies for piperacillin/tazobactam: a systematic review and meta-analysis |
Q38052888 | Clinical outcomes with extended or continuous versus short-term intravenous infusion of carbapenems and piperacillin/tazobactam: a systematic review and meta-analysis |
Q102322061 | Combination therapy of vancomycin and piperacillin/tazobactam in adult febrile neutropenia patients with haematopoietic malignancies increases the risk of acute kidney injury regardless of vancomycin trough concentration |
Q71624486 | Comment: piperacillin/tazobactam: a new beta-lactam/beta-lactamase inhibitor combination |
Q91693359 | Comparative Effectiveness of Exclusive Exposure to Nafcillin or Oxacillin, Cefazolin, Piperacillin/Tazobactam, and Fluoroquinolones Among a National Cohort of Veterans With Methicillin-Susceptible Staphylococcus aureus Bloodstream Infection |
Q79399849 | Comparative activities of cefepime and piperacillin/tazobactam tested against a global collection of Escherichia coli and Klebsiella spp. with an ESBL phenotype |
Q44604885 | Comparative activity and spectrum of broad-spectrum beta-lactams (cefepime, ceftazidime, ceftriaxone, piperacillin/tazobactam) tested against 12,295 staphylococci and streptococci: report from the SENTRY antimicrobial surveillance program (North Ame |
Q59386991 | Comparative activity of piperacillin/tazobactam against 5625 isolates from hospitalised patients |
Q54123202 | Comparative activity of piperacillin/tazobactam against clinical isolates of extended-spectrum beta-lactamase-producing Enterobacteriaceae. |
Q73732060 | Comparative evaluation of the in vitro activity of three combinations of beta-lactams with beta-lactamase inhibitors: piperacillin/tazobactam, ticarcillin/clavulanic acid and ampicillin/sulbactam |
Q33542819 | Comparative in vitro activity of Meropenem, Imipenem and Piperacillin/tazobactam against 1071 clinical isolates using 2 different methods: a French multicentre study |
Q71861334 | Comparative in vitro activity of piperacillin/tazobactam against gram-negative bacilli |
Q73888005 | Comparative in vitro evaluation of piperacillin/tazobactam in a tertiary care hospital |
Q90918948 | Comparative incidence and excess risk of acute kidney injury in hospitalised patients receiving vancomycin and piperacillin/tazobactam in combination or as monotherapy |
Q33508983 | Comparative pharmacodynamics of intermittent and prolonged infusions of piperacillin/tazobactam using Monte Carlo simulation and steady-state pharmacokinetic data from hospitalized patients |
Q33508985 | Comparative pharmacodynamics of intermittent and prolonged infusions of piperacillin/tazobactam using Monte Carlo simulations and steady-state pharmacokinetic data from hospitalized patients |
Q43994172 | Comparative pharmacokinetic and pharmacodynamic profile of piperacillin/tazobactam 3.375G Q4H and 4.5G Q6H. |
Q40601273 | Comparative study of piperacillin/tazobactam versus imipenem/cilastatin in febrile neutropenia (1994-1996) |
Q40852055 | Comparative susceptibility profile of piperacillin/tazobactam against anaerobic bacteria |
Q91566126 | Comparing ceftolozane/tazobactam versus piperacillin/tazobactam as empiric therapy for complicated urinary tract infection in Taiwan: A cost-utility model focusing on gram-negative bacteria |
Q41513406 | Comparison between piperacillin/tazobactam and cefepime monotherapies as an empirical therapy for febrile neutropenia in children with hematological and malignant disorders: A prospective, randomized study |
Q57773615 | Comparison of Intravenous/Oral Ciprofloxacin Plus Metronidazole Versus Piperacillin/Tazobactam in the Treatment of Complicated Intraabdominal Infections |
Q91260328 | Comparison of acute kidney injury risk associated with vancomycin and concomitant piperacillin/tazobactam or cefepime in the intensive care unit |
Q67505982 | Comparison of fixed concentration and fixed ratio options for testing susceptibility of gram-negative bacilli to piperacillin and piperacillin/tazobactam |
Q46951637 | Comparison of piperacillin/tazobactam and imipenem/cilastatin, both in combination with tobramycin, administered every 6 h for treatment of nosocomial pneumonia |
Q50015025 | Comparison of the Nephrotoxicity of Vancomycin in Combination With Cefepime, Meropenem, or Piperacillin/Tazobactam: A Prospective, Multicenter Study |
Q44021739 | Comparison of the effect of ciprofloxacin and Tazocin on the incidence of meticillin-resistant Staphylococcus aureus (MRSA) in an Intensive Care Unit. |
Q96607569 | Concomitant vancomycin and piperacillin/tazobactam treatment is associated with an increased risk of acute kidney injury in Japanese patients |
Q38208157 | Continuous infusion of piperacillin/tazobactam in patients with severe infections: A possible pharmacokinetic optimisation? |
Q34490565 | Continuous infusion of piperacillin/tazobactam in septic critically ill patients--a multicenter propensity matched analysis. |
Q82876738 | Continuous infusion of piperacillin/tazobactam in ventilator-associated pneumonia: a pilot study on efficacy and costs |
Q40948657 | Continuous versus intermittent piperacillin/tazobactam infusion in infection due to or suspected pseudomonas aeruginosa |
Q91327246 | Corrigendum to "Early target attainment of continuous infusion piperacillin/tazobactam and meropenem in critically ill patients: A prospective observational study" [Journal of Critical Care 52 (2019) 75-79] |
Q42953644 | Cost-Effectiveness Evaluation of Ertapenem versus Piperacillin/Tazobactam in the Treatment of Complicated Intraabdominal Infections Accounting for Antibiotic Resistance |
Q33617939 | Cost-effectiveness of ceftolozane/tazobactam compared with piperacillin/tazobactam as empiric therapy based on the in-vitro surveillance of bacterial isolates in the United States for the treatment of complicated urinary tract infections |
Q40203385 | Cost-effectiveness of ceftolozane/tazobactam plus metronidazole compared with piperacillin/tazobactam as empiric therapy for the treatment of complicated intra-abdominal infections based on the in-vitro surveillance of bacterial isolates in the UK. |
Q45351595 | Cost-effectiveness of ceftolozane/tazobactam plus metronidazole versus piperacillin/tazobactam as initial empiric therapy for the treatment of complicated intra-abdominal infections based on pathogen distributions drawn from national surveillance da |
Q74619018 | Cost-minimization analysis of piperacillin/tazobactam versus imipenem/cilastatin for the treatment of serious infections: a Canadian hospital perspective |
Q35650111 | Cross-Canada survey of resistance of 2747 aerobic blood culture isolates to piperacillin/tazobactam and other antibiotics |
Q40344887 | Delayed-type hypersensitivity reaction to piperacillin/tazobactam in a patient with an infected total knee replacement |
Q44855148 | Determination of nontoxic concentrations of piperacillin/tazobactam for intravitreal application. An electroretinographic, histopathologic and morphometric analysis |
Q44047336 | Development and optimization of a reversed-phase high-performance liquid chromatographic method for the determination of piperacillin and tazobactam in tazocin injectable powder |
Q50066986 | Differences in suppression of regrowth and resistance despite similar initial bacterial killing for meropenem and piperacillin/tazobactam against Pseudomonas aeruginosa and Escherichia coli. |
Q42607392 | Differences in the changes in resistance patterns to third- and fourth-generation cephalosporins and piperacillin/tazobactam among Klebsiella pneumoniae and Escherichia coli clinical isolates following a restriction policy in a Greek tertiary care h |
Q35993212 | Do piperacillin/tazobactam and other antibiotics with inhibitory activity against Clostridium difficile reduce the risk for acquisition of C. difficile colonization? |
Q38848103 | Dose optimization of piperacillin/tazobactam in critically ill children. |
Q82744390 | Dosing of piperacillin/tazobactam in a morbidly obese patient |
Q36299254 | Drug Fever Induced by Piperacillin/Tazobactam in a Scoliosis Patient: A Case Report |
Q34540020 | Drug fever due to piperacillin/tazobactam loaded into bone cement |
Q40095824 | Drug fever induced by piperacillin/tazobactam in an elderly patient with underlying human immunodeficiency virus (HIV) infection |
Q91077960 | Drug utilization evaluation of Piperacillin/Tazobactam: A prospective and cross sectional investigation in tertiary care setup |
Q64128953 | Early target attainment of continuous infusion piperacillin/tazobactam and meropenem in critically ill patients: A prospective observational study |
Q50928065 | Effect of applying the new Clinical and Laboratory Standards Institute ticarcillin/clavulanic acid, piperacillin, piperacillin/tazobactam and imipenem susceptibility breakpoints for Pseudomonas aeruginosa in Hong Kong. |
Q38675320 | Effect of piperacillin/tazobactam restriction on usage and rates of acute renal failure |
Q67493290 | Effect of piperacillin/tazobactam therapy on intestinal microflora |
Q44821677 | Effect of piperacillin/tazobactam treatment on human bowel microflora |
Q45020548 | Effect of subinhibitory concentration of piperacillin/tazobactam on Pseudomonas aeruginosa |
Q44930306 | Effect of the increasing use of piperacillin/tazobactam on the incidence of vancomycin-resistant enterococci in four academic medical centers |
Q38939632 | Effectiveness and safety of generic formulation of piperacillin/tazobactam (Astaz-P) for treatment of infected patients at Siriraj Hospital |
Q40658654 | Effectiveness of piperacillin/tazobactam in the treatment of fever of unknown etiology in patients with granulocytopenia |
Q101475452 | Effects of Antibiotic Treatment with Piperacillin/Tazobactam versus Ceftriaxone on the Composition of the Murine Gut Microbiota |
Q46462987 | Effects of piperacillin/tazobactam on Clostridium difficile growth and toxin production in a human gut model |
Q36592698 | Efficacy and safety of IV/PO moxifloxacin and IV piperacillin/tazobactam followed by PO amoxicillin/clavulanic acid in the treatment of diabetic foot infections: results of the RELIEF study |
Q94701669 | Efficacy and safety of doripenem versus piperacillin/tazobactam in nosocomial pneumonia: a randomized, open-label, multicenter study |
Q71654600 | Efficacy and safety of piperacillin/tazobactam in intra-abdominal infections |
Q40393949 | Efficacy and safety of piperacillin/tazobactam in skin and soft tissue infections |
Q44416621 | Efficacy and safety of piperacillin/tazobactam versus biapenem in late elderly patients with nursing- and healthcare-associated pneumonia. |
Q43609282 | Efficacy and tolerability of piperacillin/tazobactam versus ceftazidime in association with amikacin for treating nosocomial pneumonia in intensive care patients: a prospective randomized multicenter trial |
Q40571303 | Efficacy and tolerability of prophylactic treatment with intravenous piperacillin/tazobactam in patients undergoing hematopoietic stem cell transplantation |
Q71654593 | Efficacy of piperacillin/tazobactam in the treatment of experimental intra-abdominal infections |
Q46843092 | Efficacy of the bovine antimicrobial peptide indolicidin combined with piperacillin/tazobactam in experimental rat models of polymicrobial peritonitis |
Q72956661 | Efficacy, safety and tolerance of parenteral piperacillin/tazobactam in the treatment of patients with lower respiratory tract infections |
Q53946960 | Efficacy, safety, and tolerance of piperacillin/tazobactam compared to co-amoxiclav plus an aminoglycoside in the treatment of severe pneumonia. |
Q43815756 | Elimination of the piperacillin/tazobactam combination during continuous venovenous haemofiltration and haemodiafiltration in patients with acute renal failure |
Q90039422 | Emergence of antimicrobial resistance to piperacillin/tazobactam or meropenem in the ICU: Intermittent versus continuous infusion. A retrospective cohort study |
Q80794429 | Empiric therapy for secondary peritonitis: a pharmacodynamic analysis of cefepime, ceftazidime, ceftriaxone, imipenem, levofloxacin, piperacillin/tazobactam, and tigecycline using Monte Carlo simulation |
Q54367468 | Equal efficacy of a generic piperacillin/tazobactam formulation: results of a local screening protocol. |
Q34468030 | Ertapenem versus piperacillin/tazobactam for diabetic foot infections (SIDESTEP): prospective, randomised, controlled, double-blinded, multicentre trial. |
Q40786989 | Ertapenem versus piperacillin/tazobactam for diabetic foot infections in China: a Phase 3, multicentre, randomized, double-blind, active-controlled, non-inferiority trial |
Q33516983 | Ertapenem versus piperacillin/tazobactam for the treatment of complicated infections: a meta-analysis of randomized controlled trials |
Q35057515 | Ertapenem versus piperacillin/tazobactam in the treatment of complicated intraabdominal infections: results of a double-blind, randomized comparative phase III trial. |
Q37978466 | Evaluating outcomes associated with alternative dosing strategies for piperacillin/tazobactam: a qualitative systematic review |
Q38162192 | Evaluating the appropriate use of piperacillin/tazobactam in a community health system: a retrospective chart review |
Q38925943 | Evaluation Outcomes Associated with Alternative Dosing Strategies for Piperacillin/Tazobactam: A Systematic Review and Meta-Analysis |
Q37250189 | Evaluation of Pharmacodynamic Interactions Between Telavancin and Aztreonam or Piperacillin/Tazobactam Against Pseudomonas aeruginosa, Escherichia coli and Methicillin-Resistant Staphylococcus aureus. |
Q97674932 | Evaluation of the risk of acute kidney injury with the use of piperacillin/tazobactam among adult critically ill patients |
Q40755351 | Evaluation of the use of piperacillin/tazobactam (Tazocin) at Hamad General Hospital, Qatar: are there unjustified prescriptions? |
Q43263134 | Expanded studies of piperacillin/tazobactam formulations: variations among branded product lots and assessment of 46 generic lots |
Q38714853 | Extended Infusion of Piperacillin/Tazobactam in Children |
Q38442491 | Extracorporeal Elimination of Piperacillin/Tazobactam during Molecular Adsorbent Recirculating System Therapy |
Q72170451 | FDA approved new drug bulletin: piperacillin/tazobactam (zosyn), salmeterol xinafoate (serevent) |
Q81454293 | False positivity for Aspergillus antigenemia related to the administration of piperacillin/tazobactam |
Q46468471 | False positivity of the Aspergillus galactomannan Platelia ELISA because of piperacillin/tazobactam treatment: does it represent a clinical problem? |
Q91295843 | False-positive results in the galactomannan Platelia™ Aspergillus assay with generic piperacillin/tazobactam |
Q95582370 | Generalized fixed drug eruption to piperacillin/tazobactam and review of literature |
Q41038249 | Generic piperacillin/tazobactam is not associated with galactomannan false-positivity in adult patients with cancer: a case-control study. |
Q88900133 | HLA B62 as a possible risk factor for drug reaction with eosinophilia and systemic symptoms to piperacillin/tazobactam |
Q45418219 | Hemolytic anemia as a result of piperacillin/tazobactam administration: a case report and discussion of pathophysiology |
Q73831010 | High rates of resistance to piperacillin/tazobactam among Escherichia coli and Klebsiella pneumoniae strains isolated in a Greek hospital |
Q64990162 | Higher incidence of acute kidney injury in patients treated with piperacillin/tazobactam than in patients treated with cefepime: a single-center retrospective cohort study. |
Q40219976 | Hospital Length of Stay Among Patients Receiving Intermittent Versus Prolonged Piperacillin/Tazobactam Infusion in the Intensive Care Units |
Q45049839 | Hypersensitivity reaction during prolonged use of piperacillin/tazobactam in treatment of osteomyelitis |
Q40243248 | Imipenem versus piperacillin/tazobactam for empiric treatment of neutropenic fever in adults. |
Q40505651 | Imipenem/cilastatin versus piperacillin/tazobactam plus amikacin for empirical therapy in febrile neutropenic patients: results of the COSTINE study |
Q33503896 | Immune thrombocytopenia caused by piperacillin/tazobactam |
Q58581078 | Impact of Piperacillin/Tazobactam on Nephrotoxicity in Patients with Gram-negative Bacteremia |
Q41243978 | Impact of a Dynamic Microbiological Environment on the Clinical Efficacy of Ertapenem and Piperacillin/Tazobactam in the Treatment of Complicated Community-Acquired Intra-Abdominal Infection in Spain: A Cost-Consequence Analysis |
Q40922179 | Impact of the MIC of piperacillin/tazobactam on the outcome for patients with bacteraemia due to Enterobacteriaceae: the Bacteraemia-MIC project. |
Q41873335 | In Vitro Synergy of Levofloxacin Plus Piperacillin/Tazobactam against Pseudomonas aeruginosa |
Q60169867 | In vitro Activity of Piperacillin/Tazobactam against 615 Pseudomonas aeruginosa Strains Isolated in Intensive Care Units |
Q81605655 | In vitro activity of piperacillin/tazobactam against isolates from patients enrolled in clinical trials |
Q70816336 | In vitro activity of piperacillin/tazobactam against recent clinical isolates from hospitalized patients in ten Belgian hospitals |
Q54441193 | In vitro activity of piperacillin/tazobactam and ertapenem against Bacteroides fragilis and Escherichia coli in pure and mixed cultures. |
Q42167822 | In vitro activity of piperacillin/tazobactam and other broad-spectrum antibiotics against bacteria from hospitalised patients in the British Isles |
Q74788485 | In vitro activity of piperacillin/tazobactam versus other broad-spectrum antibiotics against nosocomial gram-negative pathogens isolated from burn patients |
Q73153134 | In vitro antimicrobial activity of piperacillin/tazobactam in comparison with other broad-spectrum beta-lactams |
Q54365696 | In vitro efficiency of the piperacillin/tazobactam combination against inhibitor-resistant TEM- and complex mutant TEM-producing clinical strains of Escherichia coli. |
Q46789907 | In vitro potency evaluations of various piperacillin/tazobactam generic products compared with the contemporary branded (Zosyn, Wyeth) formulation |
Q72797160 | In vitro susceptibility of Acinetobacter baumannii to biapenem, piperacillin/tazobactam and thirteen other antimicrobial agents |
Q42769136 | In vitro synergism of ulifloxacin plus piperacillin/tazobactam against clinical isolates of Enterobacteriaceae producing extended-spectrum or AmpC-type β-lactamases |
Q87536760 | In vivo efficacy of ceftolozane against Pseudomonas aeruginosa in a rabbit experimental model of pneumonia: comparison with ceftazidime, piperacillin/tazobactam and imipenem |
Q39092509 | In vivo pharmacodynamics of piperacillin/tazobactam: implications for antimicrobial efficacy and resistance suppression with innovator and generic products. |
Q77438097 | In-vitro activity of piperacillin/tazobactam relative to other antibiotics against blood culture isolates |
Q73097378 | In-vitro pharmacodynamic studies of piperacillin/tazobactam with gentamicin and ciprofloxacin |
Q94675843 | Incidence and Risk Factors of Acute Kidney Injury in Patients Receiving Concomitant Vancomycin and Continuous-Infusion Piperacillin/Tazobactam: A Retrospective Cohort Study |
Q33335393 | Incidence and impact on clinical outcome of infections with piperacillin/tazobactam resistant Escherichia coli in ICU: a retrospective study |
Q98665337 | Incidence of Acute Kidney Injury Among Infants in the Neonatal Intensive Care Unit Receiving Vancomycin With Either Piperacillin/Tazobactam or Cefepime |
Q93120550 | Incidence of acute kidney injury among pediatric hematology/oncology patients receiving vancomycin in combination with piperacillin/tazobactam or cefepime |
Q41987133 | Increasing evidence of the nephrotoxicity of piperacillin/tazobactam and vancomycin combination therapy - what is the clinician to do? |
Q91719543 | Individualizing piperacillin/tazobactam dosing in adult patients with cystic fibrosis: can tobramycin measurements help? |
Q91709633 | Induction of plasmid-mediated AmpC β-lactamase DHA-1 by piperacillin/tazobactam and other β-lactams in Enterobacteriaceae |
Q31061843 | Influence of culture site-specific MIC distributions on the pharmacokinetic and pharmacodynamic properties of piperacillin/tazobactam and piperacillin: a data analysis |
Q45221743 | Influence of renal function on the pharmacokinetics of piperacillin/tazobactam in intensive care unit patients during continuous venovenous hemofiltration |
Q44383757 | Initial empirical antimicrobial therapy with piperacillin/tazobactam in intra-abdominal infections due to perforation of the large intestine and rectum and in postoperative complications after resection of the large intestine and rectum |
Q89597706 | Integrated Genome-Wide Analysis of an Isogenic Pair of Pseudomonas aeruginosa Clinical Isolates with Differential Antimicrobial Resistance to Ceftolozane/Tazobactam, Ceftazidime/Avibactam, and Piperacillin/Tazobactam |
Q45289238 | Intrapulmonary penetration of ceftolozane/tazobactam and piperacillin/tazobactam in healthy adult subjects |
Q42920211 | Intravenous piperacillin/tazobactam plus fluoroquinolone prophylaxis prior to prostate ultrasound biopsy reduces serious infectious complications and is cost effective |
Q42791503 | Intravitreal piperacillin/tazobactam in the management of multidrug-resistant Pseudomonas aeruginosa endophthalmitis |
Q92746142 | Invasive paediatric Elizabethkingia meningoseptica infections are best treated with a combination of piperacillin/tazobactam and trimethoprim/sulfamethoxazole or fluoroquinolone |
Q46904818 | Irreproducible piperacillin/tazobactam minimum inhibitory concentrations in microdilution tests with Escherichia coli strains |
Q80008085 | Is Tazocin (piperacillin/tazobactam) effective against non -lactamase producers? |
Q40470332 | Is prolonged infusion of piperacillin/tazobactam and meropenem in critically ill patients associated with improved pharmacokinetic/pharmacodynamic and patient outcomes? An observation from the Defining Antibiotic Levels in Intensive care unit patien |
Q80192309 | Kinetics of galactomannan in surgical patients receiving perioperative piperacillin/tazobactam prophylaxis |
Q84758162 | Kounis Syndrome induced by intravenous administration of piperacillin/tazobactam: a case report |
Q46011351 | Lack of pharmacokinetic drug interactions following concomitant administration of telavancin with aztreonam or piperacillin/tazobactam in healthy participants. |
Q89502917 | Lack of synergistic nephrotoxicity between vancomycin and piperacillin/tazobactam in a rat model and a confirmatory cellular model |
Q33331121 | Leukocytopenia, thrombocytopenia and fever related to piperacillin/tazobactam treatment--a retrospective analysis in 38 children with cystic fibrosis |
Q71114846 | Life-threatening neutropenia secondary to piperacillin/tazobactam therapy |
Q40364811 | Low-dose beta-lactam plus amikacin in febrile neutropenia: cefepime vs. piperacillin/tazobactam, a randomized trial |
Q33751132 | Meropenem and piperacillin/tazobactam prescribing in critically ill patients: does augmented renal clearance affect pharmacokinetic/pharmacodynamic target attainment when extended infusions are used? |
Q101556873 | Meropenem versus piperacillin/tazobactam for febrile neutropenia in pediatric patients: efficacy of piperacillin/tazobactam as a 1-h drip infusion four times a day |
Q40142656 | Meropenem versus piperacillin/tazobactam with or without immunoglobulin as second-line therapy for febrile neutropenia in pediatric patients |
Q41205767 | Microbiological activity of ceftolozane/tazobactam, ceftazidime, meropenem, and piperacillin/tazobactam against Pseudomonas aeruginosa isolated from children with cystic fibrosis |
Q54358083 | Microbiological equivalence of bacteriostatic and bactericidal activities of the sera from healthy volunteers receiving generic piperacillin/tazobactam (Pipertaz) and original piperacillin/tazobactam (Tazocin). |
Q38070907 | Molecular Adsorbent Recirculating System (MARS(®)) removal of piperacillin/tazobactam in a patient with acetaminophen-induced acute liver failure |
Q40484723 | Monotherapy with piperacillin/tazobactam versus cefepime as empirical therapy for febrile neutropenia in pediatric cancer patients: a randomized comparison |
Q77054783 | Monotherapy with piperacillin/tazobactam versus combination therapy with ceftazidime plus amikacin as an empiric therapy for fever in neutropenic cancer patients |
Q86380443 | More potency assay results for generic non-USA lots of piperacillin/tazobactam and initial reports for generic meropenem compounds marketed in the USA |
Q90039419 | Mortality caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae bacteremia; a case control study: alert to Enterobacteriaceae strains with high minimum inhibitory concentrations of piperacillin/tazobactam |
Q43859139 | Multicentre clinical trial on efficacy and safety of domestic piperacillin/tazobactam for treatment of acute bacterial infections |
Q72570621 | Multicentre survey of the comparative in-vitro activity of piperacillin/tazobactam against bacteria from hospitalized patients in the British Isles |
Q38511099 | Multidrug-resistant Pseudomonas aeruginosa endophthalmitis in a silicone oil-filled eye treated with piperacillin/tazobactam: report of a case and review of literature |
Q99566393 | Nephrotoxicity of concomitant piperacillin/tazobactam and teicoplanin compared with monotherapy |
Q101359589 | Nephrotoxicity of teicoplanin-based combination therapy: focus on piperacillin/tazobactam and other anti-pseudomonal β-lactams |
Q92771866 | Novel insights into the chemistry of an old medicine: A general degradative pathway for penicillins from a piperacillin/tazobactam stability study |
Q50003909 | Ocular Permeation of Topical Tazocin and Its Effectiveness in the Treatment of Pseudomonas aeruginosa Induced Keratitis in Rabbits |
Q40539790 | Once-daily oral levofloxacin monotherapy versus piperacillin/tazobactam three times a day: a randomized controlled multicenter trial in patients with febrile neutropenia |
Q80614476 | Optimising piperacillin/tazobactam dosing in paediatrics |
Q92698139 | Outcomes analysis in patients with extended-spectrum beta-lactamase bacteremia empirically treated with piperacillin/tazobactam versus carbapenems |
Q45981027 | Outcomes of extended infusion piperacillin/tazobactam for documented Gram-negative infections. |
Q92863127 | PIPERACILLIN/TAZOBACTAM IN CONTINUOUS INFUSION VERSUS INTERMITTENT INFUSION IN CHILDREN WITH FEBRILE NEUTROPENIA |
Q95516465 | Parameters influencing the pharmacokinetics/pharmacodynamics of piperacillin/tazobactam in patients with febrile neutropenia and haematological malignancy: a prospective study |
Q43916920 | Penetration of piperacillin/tazobactam (4 g/500 mg) into synovial tissue |
Q36624535 | Penetration of piperacillin/tazobactam into gynecologic tissues following a single loading dose prior to hysterectomy |
Q49428641 | Pharmacodynamic Target Attainment for Meropenem and Piperacillin/Tazobactam Using a PK/PD-based Dosing Calculator in Critically Ill Patients. |
Q96681463 | Pharmacodynamic evaluation of intermittent versus extended and continuous infusions of piperacillin/tazobactam in a hollow-fibre infection model against Klebsiella pneumoniae |
Q52231066 | Pharmacodynamic interactions of ciprofloxacin, piperacillin, and piperacillin/tazobactam in healthy volunteers. |
Q44176576 | Pharmacodynamic profiling of continuously infused piperacillin/tazobactam against Pseudomonas aeruginosa using Monte Carlo analysis |
Q46609027 | Pharmacodynamics of intermittent and continuous infusion piperacillin/tazobactam and cefepime against extended-spectrum beta-lactamase-producing organisms |
Q46122902 | Pharmacoeconomics of piperacillin/tazobactam and imipenem/cilastatin in the treatment of patients with intra-abdominal infections |
Q72811534 | Pharmacokinetic characteristics of piperacillin/tazobactam |
Q58424135 | Pharmacokinetic interaction between methotrexate and piperacillin/tazobactam resulting in prolonged toxic concentrations of methotrexate |
Q44569224 | Pharmacokinetic/pharmacodynamic modeling to predict in vivo effectiveness of various dosing regimens of piperacillin/tazobactam and piperacillin monotherapy against gram-negative pulmonary isolates from patients managed in intensive care units in 20 |
Q51796852 | Pharmacokinetics and pharmacodynamics of extended-infusion piperacillin/tazobactam in adult patients with cystic fibrosis-related acute pulmonary exacerbations. |
Q40810754 | Pharmacokinetics and pharmacodynamics of piperacillin/tazobactam during high volume haemodiafiltration in patients with septic shock |
Q44104691 | Pharmacokinetics and pharmacodynamics of piperacillin/tazobactam when administered by continuous infusion and intermittent dosing |
Q40393943 | Pharmacokinetics and tissue penetration of piperacillin/tazobactam with particular reference to its potential in abdominal and soft tissue infections |
Q53912120 | Pharmacokinetics of intraperitoneal piperacillin/tazobactam in patients on peritoneal dialysis with and without pseudomonas peritonitis. |
Q34462071 | Pharmacokinetics of piperacillin/tazobactam in cancer patients with hematological malignancies and febrile neutropenia after chemotherapy |
Q49166528 | Pharmacokinetics of tazobactam M1 metabolite after administration of piperacillin/tazobactam in subjects with renal impairment |
Q37889386 | Piperacillin and tazobactam versus clindamycin and gentamicin in the treatment of hospitalized women with pelvic infection. The Piperacillin/tazobactam Study Group. |
Q36625129 | Piperacillin/Tazobactam (ZOSYN) |
Q90001946 | Piperacillin/Tazobactam and Antibiotic-Associated Acute Kidney Injury in Critically Ill Children |
Q92619569 | Piperacillin/Tazobactam as Cause of Acute Generalized Exanthematous Pustulosis |
Q44194550 | Piperacillin/Tazobactam inducing seizures in a hemodialysed patient |
Q92416136 | Piperacillin/Tazobactam versus Tobramycin-Based Antibiotic Prophylaxis for Type III Open Fractures |
Q43802907 | Piperacillin/Tazobactam versus cefotaxime plus metronidazole for treatment of children with intra-abdominal infections requiring surgery. |
Q40471195 | Piperacillin/Tazobactam: A New Beta-Lactam/Beta-Lactamase Inhibitor Combination |
Q34096531 | Piperacillin/Tazobactam: Evaluation of Its In vitro Activity against Bacteria Isolated in Two Brazilian Hospitals and an Overview of Its Antibacterial Activity, Pharmacokinetic Properties and Therapeutic Potential |
Q83881387 | Piperacillin/tazobactam (Tazocin™) seems to be no longer responsible for false-positive results of the galactomannan assay |
Q69364580 | Piperacillin/tazobactam (YTR 830) combination. Comparative antimicrobial activity against 5889 recent aerobic clinical isolates and 60 Bacteroides fragilis group strains |
Q42260223 | Piperacillin/tazobactam Induced Myelosuppression. |
Q93608433 | Piperacillin/tazobactam administered by continuous or intermittent infusion for the treatment of nosocomial pneumonia |
Q68488621 | Piperacillin/tazobactam and ticarcillin/clavulanic acid against resistant Enterobacteriaceae |
Q40440027 | Piperacillin/tazobactam as an alternative antibiotic therapy to carbapenems in the treatment of urinary tract infections due to extended-spectrum β-lactamase-producing Enterobacteriaceae: an in silico pharmacokinetic study |
Q73113195 | Piperacillin/tazobactam compared with cefuroxime/ metronidazole in the treatment of intra-abdominal infections |
Q72574046 | Piperacillin/tazobactam compared with ticarcillin/clavulanate in community-acquired bacterial lower respiratory tract infection |
Q54736676 | Piperacillin/tazobactam continuous infusion at 12G/1.5G per day in CF patients results in target plasma-concentrations. |
Q71728536 | Piperacillin/tazobactam in comparison with clindamycin plus gentamicin in the treatment of intra-abdominal infections |
Q54631175 | Piperacillin/tazobactam in complicated urinary tract infections. |
Q54146587 | Piperacillin/tazobactam in the treatment of Klebsiella pneumoniae infections in neonates. |
Q72811538 | Piperacillin/tazobactam in the treatment of community-acquired and nosocomial respiratory tract infections: a review |
Q40670277 | Piperacillin/tazobactam in the treatment of hospitalized patients with urinary tract infections: an open non-comparative and multicentered trial |
Q42595403 | Piperacillin/tazobactam in the treatment of lower respiratory tract infections: an open non-comparative and multicentered trial. Latin American Clinical Research Group |
Q54200566 | Piperacillin/tazobactam in the treatment of polymicrobial infections. |
Q68256495 | Piperacillin/tazobactam in the treatment of serious acute soft tissue infection |
Q46962912 | Piperacillin/tazobactam in treatment of brain abscess |
Q33402228 | Piperacillin/tazobactam induced thrombocytopaenia--a delayed response |
Q40326885 | Piperacillin/tazobactam monotherapy versus piperacillin/tazobactam plus amikacin as initial empirical therapy for febrile neutropenia in children with acute leukemia |
Q40419049 | Piperacillin/tazobactam plus amikacin versus carbapenem monotherapy as empirical treatment of febrile neutropenia in childhood hematological malignancies |
Q90743340 | Piperacillin/tazobactam plus amikacin vs. piperacilin/tazobactam: treatment for children with febrile neutropenia |
Q40393011 | Piperacillin/tazobactam plus ceftazidime versus sulbactam/ampicillin plus aztreonam as empirical therapy for fever in severely neutropenic pediatric patients |
Q40729000 | Piperacillin/tazobactam plus gentamicin as empirical therapy for febrile neutropenic patients with haematological malignancy |
Q74629167 | Piperacillin/tazobactam plus tobramycin versus ceftazidime plus tobramycin as empiric therapy for fever in severely neutropenic patients |
Q53933158 | Piperacillin/tazobactam plus tobramycin versus ceftazidime plus tobramycin for the treatment of patients with nosocomial lower respiratory tract infection. Piperacillin/tazobactam Nosocomial Pneumonia Study Group. |
Q100415732 | Piperacillin/tazobactam resistance in a clinical isolate of Escherichia coli due to IS26-mediated amplification of blaTEM-1B |
Q99202016 | Piperacillin/tazobactam selects an ampC derepressed E. cloacae complex mutant in a diabetic osteoarticular infection |
Q74445707 | Piperacillin/tazobactam therapy for diabetic foot infection |
Q44206071 | Piperacillin/tazobactam versus cefepime as initial empirical antimicrobial therapy in febrile neutropenic patients: a prospective randomized pilot study. |
Q40388224 | Piperacillin/tazobactam versus cefepime for the empirical treatment of pediatric cancer patients with neutropenia and fever: a randomized and open-label study |
Q40329901 | Piperacillin/tazobactam versus cefozopran for the empirical treatment of pediatric cancer patients with febrile neutropenia |
Q43260800 | Piperacillin/tazobactam versus imipenem/cilastatin for severe diabetic foot infections: a prospective, randomized clinical trial in a university hospital |
Q72951194 | Piperacillin/tazobactam versus imipenem/cilastatin in the treatment of intra-abdominal infections |
Q74683283 | Piperacillin/tazobactam versus imipenem: a double-blind, randomized formulary feasibility study at a major teaching hospital |
Q90293380 | Piperacillin/tazobactam vs carbapenems for patients with bacterial infection: Protocol for a systematic review |
Q40489194 | Piperacillin/tazobactam vs ceftazidime in the treatment of neutropenic fever in patients with acute leukemia or following autologous peripheral blood stem cell transplantation: a prospective randomized trial |
Q79803938 | Piperacillin/tazobactam vs imipenem/cilastatin in the treatment of nosocomial pneumonia--a double blind prospective multicentre study |
Q40222930 | Piperacillin/tazobactam vs. cefoperazone/sulbactam in adult low-risk febrile neutropenia cases |
Q41125741 | Piperacillin/tazobactam: a critical review of the evolving clinical literature |
Q72956628 | Piperacillin/tazobactam: a new beta-lactam/beta-lactamase inhibitor combination |
Q34458678 | Piperacillin/tazobactam: a pharmacoeconomic review of its use in moderate to severe bacterial infections |
Q33649676 | Piperacillin/tazobactam: an updated review of its use in the treatment of bacterial infections |
Q54348027 | Point mutations in the inc antisense RNA gene are associated with increased plasmid copy number, expression of blaCMY-2 and resistance to piperacillin/tazobactam in Escherichia coli. |
Q37306664 | Population Pharmacokinetic Analysis of Piperacillin/Tazobactam in Korean Patients with Acute Infections |
Q90190596 | Population Pharmacokinetic Modeling and Pharmacodynamic Target Attainment Simulation of Piperacillin/Tazobactam for Dosing Optimization in Late Elderly Patients with Pneumonia |
Q41306032 | Population Pharmacokinetics and Pharmacodynamics of Piperacillin/Tazobactam in Patients with Nosocomial Infections |
Q46588566 | Population pharmacokinetics and pharmacodynamics of piperacillin/tazobactam in patients with complicated intra-abdominal infection |
Q45308970 | Population pharmacokinetics of piperacillin/tazobactam in critically ill young children |
Q42684527 | Population pharmacokinetics of piperacillin/tazobactam in neonates and young infants |
Q40186288 | Population pharmacokinetics of the piperacillin component of piperacillin/tazobactam in pediatric oncology patients with fever and neutropenia |
Q44019734 | Potency and antimicrobial spectrum update for piperacillin/tazobactam (2000): emphasis on its activity against resistant organism populations and generally untested species causing community-acquired respiratory tract infections |
Q46530464 | Preliminary study on the release of DNA from Pseudomona aeruginosa induced by piperacillin/tazobactam in vitro |
Q38245389 | Prolonged vs intermittent infusion of piperacillin/tazobactam in critically ill patients: a narrative and systematic review. |
Q40520288 | Proposed breakpoint of piperacillin/tazobactam against extended spectrum β-lactamases producing bacteria in bacteremia |
Q44852610 | Prospective randomized comparison study of piperacillin/tazobactam and meropenem for healthcare-associated pneumonia in Japan |
Q34729874 | Prospective randomized study of piperacillin/tazobactam therapy of surgically treated intra-abdominal infection. The Piperacillin/Tazobactam Intra-Abdominal Infection Study Group. |
Q33551807 | Proteomic analysis of Escherichia coli with experimentally induced resistance to piperacillin/tazobactam |
Q34687596 | Proteomic changes in Bacteroides fragilis exposed to subinhibitory concentration of piperacillin/tazobactam |
Q45162945 | Randomized comparison of piperacillin/tazobactam versus imipenem/cilastatin in the treatment of patients with intra-abdominal infection |
Q54444593 | Randomized, multicenter, double-blind study of efficacy, safety, and tolerability of intravenous ertapenem versus piperacillin/tazobactam in treatment of complicated intra-abdominal infections in hospitalized adults. |
Q44707193 | Randomized, prospective and comparative clinical trial of piperacillin/tazobactam versus ceftriaxone plus ornidazole in the treatment of biliary tract infections |
Q34547453 | Rash associated with piperacillin/tazobactam administration in infectious mononucleosis |
Q44665006 | Reduction in multiresistant nosocomial infections in neonates following substitution of ceftazidime with piperacillin/tazobactam in empiric antibiotic therapy |
Q80008077 | Reply: Is Tazocin (piperacillin/tazobactam) effective against non -lactamase producers? |
Q77747857 | Resistance patterns of Pseudomonas aeruginosa to carbapenems and piperacillin/tazobactam |
Q92614468 | Resistance to piperacillin/tazobactam in Escherichia coli resulting from extensive IS26-associated gene amplification of blaTEM-1 |
Q50802868 | Results of a multicenter, controlled, randomized clinical trial evaluating the combination of piperacillin/tazobactam and tigecycline in high-risk hematologic patients with cancer with febrile neutropenia. |
Q71654604 | Results of the North American trial of piperacillin/tazobactam compared with clindamycin and gentamicin in the treatment of severe intra-abdominal infections. Investigators of the Piperacillin/Tazobactam Intra-abdominal Infection Study Group |
Q54200563 | Review of piperacillin/tazobactam in the treatment of bacteremic infections and summary of clinical efficacy. |
Q35811642 | Risk factors for kidney injury during vancomycin and piperacillin/tazobactam administration, including increased odds of injury with combination therapy |
Q104682639 | Risk of acute kidney injury and Clostridioides difficile infection with piperacillin/tazobactam, cefepime and meropenem with or without vancomycin |
Q40306703 | Role of piperacillin/tazobactam as a carbapenem-sparing antibiotic for treatment of acute pyelonephritis due to extended-spectrum β-lactamase-producing Escherichia coli |
Q96016944 | Safety and tolerability of i.v. push piperacillin/tazobactam within an emergency department |
Q44951211 | Safety evaluation of piperacillin/tazobactam in very low birth weight infants |
Q90678063 | Safety of Subcutaneous Piperacillin/Tazobactam Administration Compared to Intravenous Administration: Propensity Score-Matched Cohort Study |
Q72956643 | Safety profile of piperacillin/tazobactam in phase I and III clinical studies |
Q47213579 | Selection of piperacillin/tazobactam infusion mode guided by SOFA score in cancer patients with hospital-acquired pneumonia: a randomized controlled study |
Q44845058 | Serum bactericidal activity of piperacillin/tazobactam against Staphylococcus aureus, piperacillin-susceptible and piperacillin-resistant Escherichia coli and Pseudomonas aeruginosa |
Q40179593 | Serum piperacillin/tazobactam pharmacokinetics in a morbidly obese individual |
Q89972654 | Severe acute hypokalaemia associated with piperacillin/tazobactam in an HIV-infected patient under antiretroviral therapy with tenofovir alafenamide: case report and literature review |
Q33408895 | Severe bone marrow suppression and hepatic dysfunction caused by piperacillin/tazobactam |
Q46638787 | Shelf lives of aseptically prepared medicines--stability of piperacillin/tazobactam in PVC and non-PVC bags |
Q96645009 | Short Versus Extended Duration Vancomycin and Piperacillin/Tazobactam and the Incidence of Acute Kidney Injury in Noncritically Ill Patients |
Q50089280 | Simplifying Piperacillin/Tazobactam Dosing: Pharmacodynamics of Utilizing Only 4.5 or 3.375 g Doses for Patients With Normal and Impaired Renal Function |
Q40160630 | Single-Dose Pharmacokinetics of Piperacillin/Tazobactam in Hispaniolan Amazon Parrots ( Amazona ventralis ). |
Q89507243 | Stability of Meropenem and Piperacillin/Tazobactam with Heparin in Various Peritoneal Dialysis Solutions |
Q39212088 | Stability of aseptically prepared tazocin solutions in polyvinyl chloride bags |
Q43281923 | Steady-state pharmacokinetics and pharmacodynamics of piperacillin/tazobactam administered by prolonged infusion in hospitalised patients |
Q44825035 | Steady-state plasma and intrapulmonary concentrations of piperacillin/tazobactam 4 g/0.5 g administered to critically ill patients with severe nosocomial pneumonia |
Q35891315 | Study of the comparative activity of piperacillin/tazobactam with currently available antibiotics against 8206 aerobic isolates |
Q50358121 | Sudden hearing loss in a patient receiving piperacillin/tazobactam and daptomycin for diabetic foot infection. |
Q84244202 | Superior in vitro activity of ertapenem and piperacillin/tazobactam against recent clinical isolates of Proteus mirabilis from intra-abdominal infections (SMART 2009-2010) |
Q72570609 | Susceptibility of 539 gram-positive and gram-negative anaerobes to new agents, including RP59500, biapenem, trospectomycin and piperacillin/tazobactam |
Q54130681 | Susceptibility survey of piperacillin/tazobactam and some beta-lactam comparators in Italy. |
Q42388733 | Suspected drug reaction with piperacillin/tazobactam, in a premature infant |
Q91664395 | Synthesis and evaluation of polymeric micelle containing piperacillin/tazobactam for enhanced antibacterial activity |
Q46263829 | System-wide implementation of the use of an extended-infusion piperacillin/tazobactam dosing strategy: feasibility of utilization from a children's hospital perspective |
Q38819770 | Target attainment analysis and optimal sampling designs for population pharmacokinetic study on piperacillin/tazobactam in neonates and young infants |
Q47373329 | Target attainment with continuous dosing of piperacillin/tazobactam in critical illness: a prospective observational study |
Q85962587 | Temocillin and piperacillin/tazobactam resistance by disc diffusion as antimicrobial surrogate markers for the detection of carbapenemase-producing Enterobacteriaceae in geographical areas with a high prevalence of OXA-48 producers |
Q87972559 | The Cost of Vancomycin and Piperacillin/Tazobactam Treatment |
Q54261702 | The Cost of Vancomycin and Piperacillin/Tazobactam Treatment-Reply. |
Q54237274 | The activity of piperacillin/tazobactam against clinical isolates collected in 20 UK centres and the design of a disc test for susceptibility testing. |
Q90573004 | The association of acute kidney injury with the concomitant use of vancomycin and piperacillin/tazobactam in children: A systematic review and meta-analysis |
Q34325764 | The ecology of antibiotic use in the ICU: homogeneous prescribing of cefepime but not tazocin selects for antibiotic resistant infection |
Q38819361 | The effect of a piperacillin/tazobactam shortage on antimicrobial prescribing and Clostridium difficile risk in 88 U.S. medical centers. |
Q72956667 | The efficacy and safety of piperacillin/tazobactam in the therapy of bacteraemia |
Q46533701 | The efficacy of intravitreal piperacillin/tazobactam in rabbits with experimental Staphylococcus epidermidis endophthalmitis: a comparison with vancomycin |
Q46473308 | The efficacy of piperacillin/tazobactam in experimental Pseudomonas aeruginosa endophthalmitis: a histopathological and microbiological evaluation |
Q46172279 | The impact of different renal function measuring methods on the dosages of meropenem, piperacillin/tazobactam and cefepime in critically ill patients |
Q44133712 | The impact of the increased use of piperacillin/tazobactam on the selection of antibiotic resistance among invasive Escherichia coli and Klebsiella pneumoniae isolates |
Q44039660 | The in-vitro activity of piperacillin/tazobactam, ciprofloxacin, ceftazidime and imipenem against multiple resistant gram-negative bacteria |
Q43125603 | The interaction between piperacillin/tazobactam and assays for Aspergillus galactomannan and 1,3-beta-D-glucan in patients without risk factors for invasive fungal infections |
Q72811542 | The treatment of severe intra-abdominal infections: the role of piperacillin/tazobactam |
Q44513902 | The unexpected benefits of the national piperacillin/tazobactam shortage on antibiotic stewardship |
Q31024483 | The use of piperacillin/tazobactam (in association with amikacin) in neonatal sepsis: efficacy and safety data |
Q92567947 | Therapeutic drug monitoring-based dose optimisation of piperacillin/tazobactam to improve outcome in patients with sepsis (TARGET): a prospective, multi-centre, randomised controlled trial |
Q93040611 | Therapeutic drug monitoring-guided continuous infusion of piperacillin/tazobactam significantly improves pharmacokinetic target attainment in critically ill patients: a retrospective analysis of four years of clinical experience |
Q72956634 | Therapy of soft tissue infections with piperacillin/tazobactam |
Q96123835 | Time above the minimum inhibitory concentration of piperacillin/tazobactam as a predictor of outcome in Pseudomonas aeruginosa bacteraemia |
Q73508333 | Time-kill study of the activity of trovafloxacin compared with ciprofloxacin, sparfloxacin, metronidazole, cefoxitin, piperacillin and piperacillin/tazobactam against six anaerobes |
Q40641112 | Tolerability of piperacillin/tazobactam in children and adolescents after high dose radio-/chemotherapy and autologous stem cell transplantation |
Q43087521 | Topical piperacillin/tazobactam for recalcitrant pseudomonas aeruginosa keratitis. |
Q34626378 | Treating pneumonia in critical care in the United Kingdom following failure of initial antibiotic: a cost-utility analysis comparing meropenem with piperacillin/tazobactam |
Q72544894 | Treatment of hospitalized patients with complicated skin and skin structure infections: double-blind, randomized, multicenter study of piperacillin-tazobactam versus ticarcillin-clavulanate. The Piperacillin/Tazobactam Skin and Skin Structure Study |
Q92159125 | Urinary piperacillin/tazobactam pharmacokinetics in vitro to determine the pharmacodynamic breakpoint for resistant Enterobacteriaceae |
Q43479288 | Use of piperacillin/tazobactam as empirical monotherapy in the treatment of bacterial infections in a resuscitation department |
Q98562945 | Vancomycin plus piperacillin/tazobactam and acute kidney injury risk: A review of the literature |
Q44342540 | Variable susceptibility to piperacillin/tazobactam amongst Klebsiella spp. with extended-spectrum beta-lactamases |
Q42233062 | Y-site compatibility of vancomycin and piperacillin/tazobactam at commonly utilized pediatric concentrations |
Q41714355 | Zosyn (piperacillin/tazobactam) reformulation: Expanded compatibility and coadministration with lactated Ringer's solutions and selected aminoglycosides |
Q61842395 | [Antibiotic prophylaxis in cesarean section -- piperacillin versus piperacillin/tazobactam in 300 cesarean sections] |
Q54214252 | [Bacteremia by Escherichia coli resistant to amoxycillin/clavulanic acid, ampicillin/sulbactam and piperacillin/tazobactam] |
Q73283478 | [Clinico-laboratory study of piperacillin/tazobactam in the treatment of patients with would infection] |
Q94602523 | [Combinatorial Vancomycin and Piperacillin/Tazobactam Results in Elevated Vancomycin Trough Concentration and Acute Kidney Injury: A Case Report] |
Q72143413 | [Drugs: piperacillin/tazobactam] |
Q54573785 | [Effect of piperacillin/tazobactam on the anti-infection resistance in patients with infections in the peritoneal cavity]. |
Q87905620 | [Enterobacteriaceae susceptibility to piperacillin/tazobactam in a Chilean pediatric hospital] |
Q54112263 | [Evaluation of in vitro susceptibility of hospital bacterial isolates to piperacillin and tazocin (piperacillin/tazobactam]. |
Q101238477 | [Investigation of Pseudomonas aeruginosa Biofilm Formation and Quorum Sensing Genes in Piperacillin/Tazobactam and Ciprofloxacin Sub-minimal Inhibitory Concentrations] |
Q104800702 | [Pharmacokinetics and therapeutic monitoring of piperacillin/tazobactam] |
Q53715745 | [Piperacillin/Tazobactam Shortage: Central Restriction and Alternative Recommendations as Effective Antibiotic-Stewardship Intervention at a Maximal Care Hospital]. |
Q73283473 | [Piperacillin/tazobactam in the treatment of abdominal sepsis in patients with peritonitis] |
Q98775245 | [Plasmatic concentracion of piperacillin/tazobactam in pediatric patients on ECMO support. Preliminary analysis] |
Q91581759 | [Risk of Acute Kidney Injury in Patients Treated with Vancomycin and Piperacillin/Tazobactam Compared to Vancomycin and Meropenem or Doripenem: A Retrospective Cohort Study] |
Q53739006 | [Usefulness of piperacillin/tazobactam resistance as a predictor of OXA-48 carbapenemase in Enterobacteriaceae]. |
Q37155 | World Health Organization Model List of Essential Medicines | has part(s) | P527 |
Arabic (ar / Q13955) | https://ar.wikipedia.org/wiki/بيبراسيلين/تازوباكتام | wikipedia |
https://en.wikipedia.org/wiki/Piperacillin/tazobactam | wikipedia | |
https://es.wikipedia.org/wiki/Piperacilina/tazobactam | wikipedia | |
Persian (fa / Q9168) | https://fa.wikipedia.org/wiki/پیپراسیلین/تازوباکتام | wikipedia |
https://fr.wikipedia.org/wiki/Pipéracilline/tazobactam | wikipedia | |
https://he.wikipedia.org/wiki/פיפרצילין/טזובקטם | wikipedia | |
https://hy.wikipedia.org/wiki/Պիպերացիլին/տազոբակտամ | wikipedia | |
ピペラシリン・タゾバクタム | wikipedia | |
or | https://or.wikipedia.org/wiki/ପିପେରାସିଲିନ/ଟାଜୋବାକ୍ଟମ | wikipedia |
https://pt.wikipedia.org/wiki/Piperacilina/tazobactam | wikipedia | |
https://ro.wikipedia.org/wiki/Piperacilină/tazobactam | wikipedia | |
Serbo-Croatian (sh / Q9301) | https://sh.wikipedia.org/wiki/Piperacilin/tazobaktam | wikipedia |
https://sr.wikipedia.org/wiki/Piperacilin/tazobaktam | wikipedia | |
https://vi.wikipedia.org/wiki/Piperacillin/tazobactam | wikipedia |
Search more.